0
0
December 7, 2025
NEW ORLEANS — In a potentially pivotal development for blood cancer treatment, Regeneron Pharmaceuticals announced Saturday that its experimental combination therapy eliminated all signs of disease in a small group of patients with previously untreated diffuse large B-cell lymphoma (DLBCL). The findings, presented at the American Society of Hematology (ASH) Annual Meeting, suggest that the bispecific antibody odronextamab could one day challenge the decades-old standard of care for this aggressive cancer.
The early-stage results from the Phase 3 OLYMPIA-3 trial showed that patients receiving the highest tested dose of odronextamab combined with standard chemotherapy achieved a 100% complete response rate, meaning their cancer was no longer detectable after treatment. While the sample size was small, the data signals a promising shift toward using potent immunotherapy earlier in the treatment course, rather than reserving it for patients who have already exhausted other options.
Unprecedented Early Results
The OLYMPIA-3 trial is designed to evaluate odronextamab—a “bispecific” antibody that simultaneously binds to cancer cells and the body’s immune T-cells—in combination with the standard chemotherapy regimen known as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone).
In the dose-finding portion of the study, researchers treated patients with previously untreated DLBCL, the most common form of non-Hodgkin lymphoma. Among the 13 patients who received the 160 mg dose of odronextamab plus CHOP:
-
100% achieved an objective response, meaning their tumors shrank significantly.
-
100% achieved a complete response (CR), with no evidence of cancer remaining.
-
The lower 80 mg dose cohort (9 patients) showed a 78% objective response rate and a 44% complete response rate.
“The 160 mg dose demonstrated compelling efficacy, leading to its selection for the randomized portion of the study,” said Dr. Jean-Marie Michot, a lead investigator on the trial and hematologist at Gustave Roussy in Villejuif, France. “To see a complete response in every patient in this cohort is a remarkable early signal, though we must validate this in the larger population.”
Mechanism of Action: Bridging the Immune Gap
Odronextamab represents a class of drugs known as CD20xCD3 bispecific antibodies. Unlike traditional antibodies that target a single marker, bispecifics act as a bridge. One arm of the drug grabs onto CD20, a protein found on the surface of B-cell lymphoma cells. The other arm latches onto CD3, a protein on T-cells, which are the soldiers of the immune system. This physical connection forces the T-cells to recognize and destroy the cancer cells.
Currently, the standard first-line treatment for DLBCL is “R-CHOP,” a combination of the monoclonal antibody rituximab and chemotherapy. While R-CHOP cures approximately 60-70% of patients, those who do not respond or who relapse often face a poor prognosis. Regeneron’s goal with OLYMPIA-3 is to see if swapping rituximab for the more potent odronextamab (O-CHOP) can improve cure rates and prevent relapses.
Safety and Side Effects
Immunotherapies can trigger potent side effects, and safety was a primary focus of this early trial phase. The most notable side effect associated with bispecific antibodies is Cytokine Release Syndrome (CRS), a systemic inflammatory response that can cause fever and organ strain.
In this study, CRS was common but generally manageable. It occurred primarily during the initial “step-up” dosing period, designed to acclimate the body to the drug. Importantly, no high-grade (Grade 3 or higher) CRS events were reported in the 160 mg cohort. However, infections were a significant concern, affecting over 80% of patients across both dose levels, highlighting the need for careful monitoring and infection prophylaxis in future trials.
Expert Perspectives and Context
Dr. Israel Lowy, Senior Vice President of Translational and Clinical Sciences for Oncology at Regeneron, emphasized the strategic importance of these findings. “Moving powerful immunotherapies into the first-line setting is the next frontier. If we can eradicate the disease more effectively at the start, we may spare patients the physical and emotional toll of relapsed disease and subsequent treatments like CAR-T therapy or stem cell transplants.”
Independent oncologists at the ASH meeting viewed the data with “cautious optimism.” Dr. Sarah Collins, a lymphoma specialist not involved in the study, commented, “A 100% response rate is headline-grabbing, but n=13 is a very small number in oncology. The true test will be the randomized Phase 3 trial where O-CHOP goes head-to-head against R-CHOP. That said, this is the kind of signal that justifies moving forward aggressively.”
Implications for Patients
For the general public and patients diagnosed with DLBCL, these results offer a glimpse into the future of cancer care. Currently, odronextamab is investigational and not yet FDA-approved for this indication. However, if the larger Phase 3 trial confirms these results, it could redefine the “gold standard” of treatment that has been in place for nearly two decades.
This development underscores a broader trend in oncology: “front-line” immunotherapy. Rather than waiting for chemotherapy to fail, doctors are increasingly looking to use the immune system’s full power immediately after diagnosis.
Limitations and Next Steps
While the efficacy data is pristine, the study’s limitations include its small size and lack of long-term follow-up. It is not yet known if these complete responses will translate into long-term cures or if the cancer will return. Additionally, the safety profile, particularly the risk of infections, will need to be balanced against the clinical benefit in a larger, more diverse patient population.
Regeneron has confirmed that the Phase 3 trial will now proceed with the 160 mg dose, comparing O-CHOP directly against the standard R-CHOP. Results from this larger study will likely not be available for several years.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References:
-
Michot, J. M., et al. (2025). “Odronextamab plus chemotherapy in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): First results from part 1 of the Phase 3 OLYMPIA-3 study.” Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, New Orleans, LA. Abstract #65.
-
Regeneron Pharmaceuticals. (2025, December 6). “Regeneron’s experimental therapy combo effective in untreated cancer patients.” Reuters.
